Medical Use
Poteligeo is a monoclonal antibody targeting CC chemokine receptor type 4 (CCR4), used to treat adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome, which are rare forms of non-Hodgkin lymphoma, after at least one prior systemic therapy.
Recommended Dosage: The recommended dose is 1 mg/kg administered as an intravenous infusion over a minimum of 60 minutes.
Administration Schedule:
- -Initial 28-Day Cycle: Administer on days 1, 8, 15, and 22.
- -Subsequent 28-Day Cycles: Administer on days 1 and 15 until disease progression or unacceptable toxicity occurs. Ensure the injection is given within 2 days of the scheduled dose.
Missed Dose: If a dose is missed, administer it as soon as possible and then continue with the regular dosing schedule. Do not administer subcutaneously or via rapid intravenous injection.
Premedication: For the first infusion, premedicate with acetaminophen and diphenhydramine to reduce the risk of infusion-related reactions.
Warning & Precautions
Severe Skin Reactions: Poteligeo can cause fatal and life-threatening skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Rash is a common side effect. Monitor patients for rashes throughout treatment. Manage dermatologic toxicity and consider a skin biopsy to differentiate between drug reaction and disease progression. Permanently discontinue mogamulizumab for SJS, TEN, or any severe (Grade 4) reaction. If SJS/TEN is suspected, stop treatment and do not restart unless ruled out and the skin reaction resolves to Grade 1 or less.
Infusion Reactions: Fatal and severe infusion reactions have been reported, mostly occurring during or shortly after the first infusion, but can also happen with subsequent infusions. Symptoms include nausea, chills, fever, rigors, headache, tachycardia, and vomiting. Premedicate with acetaminophen and diphenhydramine for the first infusion. Monitor patients closely for infusion reactions, interrupt the infusion for any grade reaction, and treat promptly.
Infections: Serious and fatal infections, including pneumonia, sepsis, and skin infections, have occurred. In clinical trials, 18% of patients treated with mogamulizumab experienced Grade 3 or higher infections. Monitor for signs of infection and treat promptly.
Immune-Mediated Complications: Fatal and severe immune-mediated complications can occur. Interrupt or permanently discontinue mogamulizumab for suspected immune-mediated side effects. Weigh the benefits and risks in patients with a history of autoimmune disease.
Transplant Complications: Increased risks of transplant complications, including severe acute graft-versus-host disease (GVHD), steroid-refractory GVHD, and transplant-related death, may occur in patients who receive allogeneic HSCT after mogamulizumab. Monitor patients closely for early signs of transplant-related complications.
Pregnancy and Breastfeeding: Mogamulizumab can cause fetal harm. Verify pregnancy status in women of reproductive age before starting treatment. Women of reproductive potential should use effective contraception during treatment and for at least three months after the last dose. Breastfeeding is not recommended during treatment and for at least two months after the final dose due to the potential for serious side effects in the breastfed child.
Documentation Availability
Documents required to import POTELIGEO to India?
POTELIGEO (Mogamulizumab-kpkc) Injections can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing POTELIGEO (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for Poteligeo®?
The generic name for Poteligeo® is Mogamulizumab-kpkc.
Who manufactures Poteligeo®?
Poteligeo® is manufactured by Kyowa Kirin, Inc.
Is Poteligeo® FDA approved?
Yes, Poteligeo® was approved by the FDA on August 8, 2018.
What is the dosage and form of Poteligeo®?
Poteligeo® is available as an injection: 20 mg/5 mL (4 mg/mL) clear to slightly opalescent colorless solution in a single-dose vial for intravenous use.
What are the most common side effects of Poteligeo®?
Common side effects include fatigue, rash, diarrhea, musculoskeletal pain, upper respiratory tract infection, and infusion-related reactions.
How much does Poteligeo® cost in India?
The cost of Poteligeo® (mogamulizumab) in India is relatively low and can vary. For authentic procurement, you can reach out to the Rx4u team.
What are the storage conditions for Poteligeo®?
Poteligeo® should be stored in its original carton under refrigeration at 2°C to 8°C (36°F to 46°F) to protect it from light. Do not freeze or shake the vials.
Is it safe to buy Poteligeo® online in India?
Yes, you can safely purchase Poteligeo® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
